Developing point-of-care CAR T manufacturing
European Pharmaceutical Review
DECEMBER 27, 2023
Currently CAR T-cell therapy is approved for three indications: acute lymphoblastic leukaemia (ALL), non-hodgkin lymphoma (NHL), and multiple myeloma (MM) – and the strongest correlation between CAR T-cell efficacy and persistence has been demonstrated in ALL. This is in addition to its considerable price tag.
83 
Let's personalize your content